3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
16
Carboplatin
10
Paclitaxel
8
Nivolumab
7
Bevacizumab
6
Gemcitabine
4
Fulvestrant
4
Cisplatin
4
olaparib
3
lenvatinib
3
abemaciclib
3
PM 01183
3
Oxaliplatin
3
Leucovorin
3
Letrozole
3
Docetaxel
3
AZD5305
3
tisotumab vedotin
2
spartalizumab
2
sarilumab
2
sargramostim
2
sacituzumab govitecan
2
ribociclib
2
palbociclib
2
epacadostat
2
enzalutamide
2
dostarlimab
2
cemiplimab
2
anlotinib
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Endometrial Neoplasms
×
Imlunestrant
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled